Mutations in the neuronal voltage-gated sodium channel genes SCN1A and SCN2A are associated with inherited epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome (severe myoclonic epilepsy of infancy). The clinical presentation and severity of these epilepsies vary widely, even in people with the same mutation, suggesting the action of environmental or genetic modifiers. To gain support for the hypothesis that genetic modifiers can influence clinical presentation in patients with SCN1A-derived GEFS+, we used mouse models to study the effect of combining the human GEFS+ mutation SCN1A-R1648H with SCN2A, KCNQ2, and SCN8A mutations. Knock-in mice heterozygous for the R1648H mutation (Scn1a RH/+ ) have decreased thresholds to induced seizures and infrequent spontaneous seizures, whereas homozygotes display spontaneous seizures and premature lethality. Scn2a Q54 transgenic mice have a mutation in Scn2a that results in spontaneous, adult-onset partial motor seizures, and mice carrying the Kcnq2-V182M mutation exhibit increased susceptibility to induced seizures, and rare spontaneous seizures as adults. Combining the Scn1a-R1648H allele with either Scn2a Q54 or Kcnq2 V182M/+ results in early-onset, generalized tonic-clonic seizures and juvenile lethality in double heterozygous mice. In contrast, Scn8a mutants exhibit increased resistance to induced seizures. Combining the Scn1a-R1648H and Scn8a-med-jo alleles restores normal thresholds to flurothyl-induced seizures in Scn1a RH/+ heterozygotes and improved survival of Scn1a RH/RH homozygotes. Our results demonstrate that variants in Scn2a, Kcnq2, and Scn8a can dramatically influence the phenotype of mice carrying the Scn1a-R1648H mutation and suggest that ion channel variants may contribute to the clinical variation seen in patients with monogenic epilepsy.
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Introduction
During the past 15 years, research has revealed several genes underlying rare monogenic forms of idiopathic generalized epilepsy (IGE); however, there has been less progress towards the identification of genes involved in the more common, genetically complex forms of IGE (Greenberg and Pal, 2007; Heron et al., 2007; Tan et al., 2006) . Many of the genes now known to cause monogenic forms of epilepsy encode neuronal ion channel subunits, including voltage-gated sodium and potassium channels. Mutations in the voltage-gated sodium channels SCN1A, SCN2A, and SCN1B result in genetic (generalized) epilepsy with febrile seizures plus (GEFS+) (Escayg et al., 2000; Sugawara et al., 2001; Wallace et al., 1998) . We recently generated a mouse model of GEFS+ by introducing the human SCN1A-R1648H GEFS+ mutation, which was identified in a large pedigree with 13 affected members, into the orthologous mouse Scn1a gene (Martin et al., 2010) . Scn1a R1648H/+ heterozygous mutants (Scn1a
) display a normal lifespan, reduced thresholds to flurothyl-and hyperthermia-induced seizures, and infrequent spontaneous generalized seizures as adults (Martin et al., 2010) . Scn1a RH/RH homozygous mice exhibit spontaneous generalized seizures and have an average lifespan of 18.5 days. Cortical interneurons from Scn1a RH/+ and Scn1a RH/RH mice display slowed recovery from inactivation, increased use-dependence, and a reduced ability to fire action potentials. These electrophysiological abnormalities are predicted to reduce the level of GABAergic inhibition, providing a mechanism for seizure generation (Martin et al., 2010) . Mutations in the voltage-gated sodium channel SCN2A have also been associated with human epilepsy syndromes, including GEFS+ and benign familial neonatal-infantile seizures (BFNIS) (Meisler and Kearney, 2005) . The transgenic mouse model Scn2a Q54 has a gain-offunction mutation in Scn2a and a progressive epilepsy phenotype characterized by partial motor seizures that begin in the second month of life, followed by the development of secondary generalized seizures and a reduced lifespan. Hippocampal pyramidal neurons Neurobiology of Disease 41 (2011) 655-660 
